pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Characteristics of the 674 studies included in this review
| Characteristics | |
|---|---|
| Study, n | 674 |
| Country, n | 100 |
| Received or online accessed date, No. (%) | |
| The 1st quarter of 2020 | 26 (4.0) |
| The 2nd quarter of 2020 | 219 (32.5) |
| The 3rd quarter of 2020 | 143 (21.2) |
| The 4th quarter of 2020 | 131 (19.4) |
| The 1st quarter of 2021 | 100 (14.8) |
| The 2nd quarter of 2021 | 52 (7.7) |
| The 3rd quarter of 2021 | 1 (0.1) |
| Study design, No. (%) | |
| Randomized controlled trials | 26 (3.9) |
| Cohort studies | 62 (9.2) |
| Cross-sectional studies | 4 (0.6) |
| Case-control studies | 1 (0.1) |
| Case reports | 10 (1.5) |
| Survey/interview studies | 118 (17.5) |
| Descriptive studies | 361 (53.6) |
| Others | 92 (13.4) |
| Practice setting, No. (%) | |
| Outpatient | 257 (38.1) |
| Inpatient | 169 (25.1) |
| In- and outpatient | 112 (16.6) |
| Nursing facility | 9 (1.3) |
| Others7 | 127 (18.8) |
| Subjects, No. (%) | |
| COVID-19-positive patients | 1127 (33.7) |
| COVID-19 high-risk population | 230 (34.1) |
| General population | 45 (6.7) |
| Healthcare workers | 79 (11.7) |
| Others | 93 (13.8) |
| The number of reported studies on the effects of pharmacist intervention, No. (%) | 54 (8.0) |